Regarding alkylating agents, the addition of veliparib has not proved to provide any benefit to cyclophosphamide when treating platinum-resistant relapsed ovarian cancers in germline BRCA1/2 mutated patients [72], and results are not available from its combination with temozolamide (NCT00526617, NCT01113957). This evidence concerns the gene BRCA1 and ovarian cancer.